English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduAn investigational medication designated TAS-303 shows efficacy and safety in treatment of women with stress urinary incontinence (SUI), reports a placebo-controlled clinical trial in the August issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Tag: Clinical Trial
Antibody-Drug Conjugate Highly Effective in Preventing Recurrence in Patients with Early Stage HER2+ Breast Cancer, Trial Finds
• 97% of HER2+, early-stage patients treated with trastuzumab emtansine (T-DM1) were free of cancer recurrence five years after treatment
• Prognostic test (HER2DX) shown helpful in identifying patients at greatest risk for recurrence
UNC Health Researchers Present Preliminary Data on Weight Loss Drugs on Alcohol Addiction
Christian Hendershot, PhD, associate professor of psychiatry and director of the Clinical and Translational Addiction Research Program at the UNC School of Medicine, presented early findings from the first completed randomized controlled trial of semaglutide for reducing alcohol consumption in heavy drinkers.
Researchers report first effective use of immunotherapy for most common subtype of colorectal cancer
These clinical trial results point to the first safe and effective use of immunotherapy for patients with microsatellite stable colorectal cancer, the most common subtype of the disease. The encouraging results of this phase I trial have prompted Dana-Farber investigators to move forward with a phase III trial of this immunotherapy combination.
Modifying homes for stroke survivors saves lives, extends independence
Researchers at Washington University School of Medicine in St. Louis have found that safety interventions – such as walkers, grab bars, ramps and other home modifications – allow many stroke survivors to keep living independently in their homes and may reduce their risk of death.
Anti-inflammatory drug celecoxib could reduce risk of colon cancer recurrence for a subset of patients
An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation.
Clinical trial shows promising results in a two-drug combination that curbs methamphetamine use
A clinical trial on a two-drug therapy for methamphetamine use disorder reduced use of the highly addictive drug for up to 12 weeks after initiation of treatment. To date there is no FDA-approved medication for it.
Neurent Medical Announces Publication of Positive Long-Term Results from Study on Chronic Rhinitis Treatment
Recent study confirms safety and efficacy of NEUROMARK® for chronic rhinitis
Drug Used to Treat Eczema May Provide Relief for Patients with Intensely Itchy Skin Diseases
Clinical Trial Finds Oral Medication Significantly Reduced Prurigo Nodularis and Chronic Pruritus of Unknown Origin Symptoms A drug approved to treat eczema provided significant improvement in the symptoms of patients with severe itching diseases that currently have no targeted treatments, according to a new study published in JAMA Dermatology.
Study Reveals Worse Clinical Outcomes in Breast Cancer Patients Who Reported Higher Pain and Stress
Secondary analyses of a phase 3 clinical trial have revealed that breast cancer patients who reported high levels of pain and stress were more likely than their study peers to experience worse invasive disease-free survival (iDFS) and worse overall survival (OS).
Trilaciclib use for prevention of hematological adverse events in chemotherapy: A meta-analysis of real-world studies and clinical trials
Background: Trilaciclib, a cyclin-dependent kinase (CDK)-4 and -6 inhibitor, is the only FDA-approved agent that preemptively protects hematopoietic stem cells from chemotherapy-induced myelosuppression (CIM) without compromising efficacy. It transiently arrests hematopoietic stem cells in the G1 phase, thus temporarily blocking progression…
RNA Inhibitor Is Shown Safe and Effective in Reducing a Wide Range of Cholesterol and Triglyceride Levels in the Blood in Mount Sinai-Led Clinical Trial
A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.
Pathways Study Genotype Data, Alliance A011502 Secondary Analysis Headline Roswell Park ASCO24 Presentations
New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park Comprehensive Cancer Center experts will deliver at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago next week.
HSS Launches Clinical Trial to Address Post-Traumatic Osteoarthritis after ACL Revision Surgery
Up to 18% of patients undergoing ACL reconstruction experience graft failure and require revision surgery, which is known to increase the risk of developing post-traumatic osteoarthritis (PTOA).
CRISPR Gene Editing Leads to Improvements in Vision for People With Inherited Blindness, Clinical Trial Shows
BRILLIANCE trial results showed 11 out of 14 treated participants experienced some improvements in vision and quality of life measures. CRISPR-based therapy was found safe with no dose-limiting toxicities reported. Mass Eye and Ear researchers say their findings support continued…
Society for Clinical Trials Presents E-MOTIVE Trial with Prestigious David Sackett Trial of the Year Award
The Society for Clinical Trials (SCT) is pleased to announce that the prestigious David Sackett Trial of the Year Award will be presented to the ”Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage (E-MOTIVE).”
Researchers Publish Final Results of Key Clinical Trial for Gene Therapy for Sickle Cell Disease
An international consortium published the final results of a key clinical trial of the gene therapy CASGEVY (exagamglogene autotemcel) for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).
Drug targeting clear cell renal cell carcinoma shows promising approach
In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC). Published in Clinical Cancer Research, the findings illustrate the potential of siRNA for cancer therapy.
Smart nanoparticles may be able to deliver drugs to heart after heart attack
Washington University’s Jianjun Guan to create custom nanoparticles to fight inflammation, fibrosis.
Molecular subtypes of advanced kidney cancer matter for treatment response
A new study published April 4 in Cancer Cell was led by Yale Cancer Center researchers, who collaborated with investigators nationally to differentiate the molecular subgroups of RCC tumors to better understand how their makeup might affect treatment responses.
L-Nutra’s Groundbreaking Study Revolutionizes Type 2 Diabetes Management Through Fasting Mimicking Nutrition Technology
Today, L-Nutra, the premier nutri-technology company, unveiled the results of a pioneering clinical trial, published in Diabetologia, which aims to redefine the approach to managing Type 2 Diabetes.
Tip Sheet: Weight loss drugs and cancer prevention, Fred Hutch at AACR, lymphedema Q&A — and new vice president and chief nursing officer
SEATTLE — April 3, 2024 — Below are summaries of recent Fred Hutchinson Cancer Center research findings, patient stories and other news. If you’re covering the American Association for Cancer Research (AACR) Annual Meeting, please see our list of and contact to set up interviews.
Combining epigenetic cancer medications may have benefit for colorectal cancers and other tumor types
A pair of medications that make malignant cells act as if they have a virus could hold new promise for treating colorectal cancers and other solid tumors, reports a study published today in Science Advances.
10 Facts about Head & Neck Cancers
Head and neck cancer is the term used to describe a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses and mouth.
Inflammation-reducing drug shows no benefit for dry age-related macular degeneration in NIH trial
The drug minocycline, an antibiotic that also decreases inflammation, failed to slow vision loss or expansion of geographic atrophy in people with dry age-related macular degeneration (AMD), according to a phase II clinical study at the National Eye Institute (NEI),…
BIDMC-led trial leads to FDA approval of coronary drug-coated balloons
In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and safety of using a drug-coated balloon in patients undergoing coronary angioplasty.
This Injectable Hydrogel Mitigates Damage to the Right Ventricle of the Heart
An injectable hydrogel can mitigate damage to the right ventricle of the heart with chronic pressure overload, according to a new study published March 6 in Journals of the American College of Cardiology: Basic to Translational Science. The study, by a research team from the University of California San Diego, Georgia Institute of Technology and Emory University, was conducted in rodents.
HIV Medication Can be Used Safely with Gender-Affirming Hormone Therapy
New research shows HIV medications can be taken at the same time as hormone treatment without losing potency of either therapy.
L-Nutra Unveils Groundbreaking Research on Fasting Mimicking Diets (FMDs) and Reduced Biological Age Score
L-Nutra Inc., a leading nutrition technology company developing evidence-based Nutrition for Longevity and Nutrition as Medicine programs, is excited to announce the release of a groundbreaking longevity and healthy aging study published in Nature Communications, a prestigious Nature portfolio journal.
Clinical trial tests combination antibody therapy in adults with advanced cancer
In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumor activity in individuals with various types of advanced cancer.
First Drug to Help Reduce Allergic Reactions to Multiple Food Allergies, Tested at Children’s and Emory, Now FDA Approved
Children’s Healthcare of Atlanta and Emory University participated in a nationwide clinical trial showing that a 16-week course of omalizumab, an injectable drug, increased the amount of peanut, tree nuts, egg, milk and wheat that some multi-food allergic children as young as one year could consume without an allergic reaction after exposure.
Research Study on Novel Rehab Program for Heart Failure Patients, Led by Wake Forest University School of Medicine, Expands to Advocate Health Site in Chicago
Wake Forest University School of Medicine, the academic core of Advocate Health, is expanding another research study to Advocate Christ Medical Center, in Oak Lawn, Illinois, just outside Chicago.
The study, which is testing a novel rehabilitation program designed for older patients hospitalized with acute heart failure, is funded by a five-year, $30 million grant, awarded to Wake Forest University School of Medicine in 2022 by the National Institute on Aging, part of the National Institutes of Health.
Mount Sinai Receives $2.6 Million Grant From PolyBio Research Foundation for Long COVID Clinical Trials
Funding will also support researching other complex illnesses and medical education
Intravascular Imaging Significantly Improves Survival, Safety, and Outcomes in Cardiovascular Stenting Procedures Over Conventional Angiography
Results from this large-scale synthesis of all prior clinical trials could increase usage of several types of high-resolution imaging for guiding interventional coronary procedures
New treatment for a rare and aggressive cancer improves survival rates in breakthrough clinical trial
An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results from a clinical trial led by Queen Mary University of London.
Dementia Researchers Share Recruitment Strategies for Pragmatic Clinical Trial
The Dementia Care (D-CARE) Study (2019-2023), which was conducted at four clinical trial sites in the U.S., compared three approaches in dementia care. Despite challenges during the COVID-19 pandemic, D-CARE successfully enrolled 2,176 racially/ethnically diverse persons with Alzheimer’s disease or related dementias and their caregivers.
CSOFT Health Sciences Releases MDR White Paper to Support EU Medical Device Compliance
CSOFT Health Sciences, leaders in clinical trial translation, are pleased to announce the launch of their co-authored white paper for medical device manufacturers seeking re-certification under the updated EU Medical Device Regulation (EU MDR), in collaboration with partner organizations Gouya Insights and GCP-Service International Ltd. & Co.KG to jointly offer manufacturers an end-to-end platform for establishing conformity with policies set to take effect by January 2028.
Dual-action drug produces positive results in patients with advanced neuroendocrine tumors, trial finds
Cabozantinib, which targets tumor cell growth and tumor blood vessel growth, sharply improved progression-free survival over placebo in patients with extra-pancreatic and pancreatic neuroendocrine tumors
Kidney cancer study shows improved outcomes for patients with advanced disease when treated with belzutifan over everolimus
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.
Clinical trial demonstrates benefits of solriamfetol for adults with ADHD
Although several medications are approved to treat attention-deficit/hyperactivity disorder (ADHD), some individuals experience limited benefits from the drugs or develop side effects from their use.
Breast Cancer at 30?
Amanda Butler and Isabella Bugatti, both just entering their 30s, were blindsided by a diagnosis that is on the rise among women their age: breast cancer.
High-dose radiation offers new treatment option for older patients with inoperable kidney tumors
Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted, high-dose radiation, a new study from Australian and Dutch researchers suggests.
Five Questions Parents Should Ask Their Child’s Oncologist About Participating in a Clinical Trial
When children undergo cancer treatment, they may be offered the chance to participate in a clinical trial. Clinical trials can provide access to new, groundbreaking therapies in a safe and controlled environment.
Ohio State first in world to participate in trial of device designed to alleviate heart failure symptoms
The Ohio State University Wexner Medical Center on Wednesday randomized the first patient in the world in a clinical trial evaluating the effectiveness of a device designed to alleviate heart failure symptoms.
Adding immune modulator to targeted therapy does not improve survival in difficult-to-treat thyroid cancer
New study results indicate that combining two separately promising therapies for radioiodine-resistant thyroid cancer does not bring any added benefit.
UC Davis Eye Center tests experimental gene therapy for wet age-related macular degeneration (AMD)
Ophthalmologists at UC Davis Health used an experimental gene therapy last month to treat a patient with wet age-related macular degeneration, or wet AMD. Wet AMD is a leading cause of vision loss among older adults. Glenn Yiu, a professor of ophthalmology at UC Davis Health, is the principal investigator for the new clinical trial.
Optical Coherence Tomography May Improve Safety and Outcomes for Stenting Procedures in Heart Disease Patients Compared to Conventional Angiography
Results from a large-scale clinical trial results could increase usage of high resolution imaging for guiding interventional coronary procedures
Small Percentage of People with Early Dementia Eligible for New Alzheimer’s Drugs
Only a small percentage of older adults who are in the early stages of Alzheimer’s disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer’s disease. The new research is published in the August 16, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. Clinical trial results for these drugs are only available in people in the early symptomatic stages of the disease, mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Study finds improved survival for incurable brain tumor, providing ‘a crack in the armor’
For the first time, researchers have found a potential drug candidate that improved outcomes for patients with a type of childhood brain tumor for which there are no effective treatments. The compound, called ONC201, nearly doubled survival for patients with diffuse midline glioma (DMG) or diffuse intrinsic pontine glioma (DIPG), compared to previous patients.
Mount Sinai Receives Significant Funding to Study Which Coronary Revascularization Procedure Best Improves Survival and Quality of Life for Women and Underserved Minority Groups
The Icahn School of Medicine at Mount Sinai will help lead and launch the first clinical trial focusing on women and minority populations to determine which coronary revascularization procedure best improves their survival and quality of life.